Ignite Creation Date:
2025-12-24 @ 9:55 PM
Ignite Modification Date:
2026-01-17 @ 5:04 AM
Study NCT ID:
NCT02858232
Status:
UNKNOWN
Last Update Posted:
2016-08-11
First Post:
2016-07-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
MASCT-I Treatment for Advanced Solid Tumor
Sponsor:
The First People's Hospital of Lianyungang
Organization:
Study Overview
Official Title:
A Single Arm, Open, Phase I/II Clinical Study of MASCT-I Treatment for Advanced Solid Tumor
Status:
UNKNOWN
Status Verified Date:
2016-07
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multiple Target Antigen Stimulating Cell Therapy (MASCT-I) is a new immunotherapy that dendritic cells(DC) was induced from autologous peripheral blood. The DC can then be loaded with antigens and re-infused. In vitro, antigen-pulsed DC can stimulate autologous T-cell proliferation and induction of autologous specific cytotoxic T-cells(CTL)，similarly re-infused. The previous research data showed that MASCT had the modest overall response and less adverse effects for Hepatocellular Carcinoma patients.
The study is aimed to evaluate the safety of MASCT-1 in patients with advanced solid tumors.
The study is aimed to evaluate the safety of MASCT-1 in patients with advanced solid tumors.
Detailed Description:
This study is divided into two stages. The first stage is the safety study in small samples, and the second stage is the sample size expansion phase.
40-50 patients with advanced or recurrent solid tumors who had failed after standard treatment will be recruited in this study.
40-50 patients with advanced or recurrent solid tumors who had failed after standard treatment will be recruited in this study.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: